Semaglutide belongs to a class of medications known as glucagon‐like peptide‐1 (GLP‐1) receptor agonists. It mimics the GLP‐1 hormone that is released in the gastrointestinal tract in response to eating. One role of GLP‐1 is to prompt the body to produce more insulin, which reduces blood glucose (sugar). GLP‐1 in higher amounts also interacts with the parts of the brain that reduce appetite and signal a feeling of fullness.
No takes yet. Share an insight, caveat, or question.
Alison Knopf (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: